uPAR mediates anticancer activity of PEDF.

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Osteosarcoma (OS) is a primary bone cancer predominantly affecting adolescents and young adults, characterized by high rates of fatal lung metastasis.
• Pigment Epithelium-Derived Factor (PEDF) has demonstrated multiple anti-OS activities, while urokinase-type Plasminogen Activator Receptor (uPAR) downregulation shows beneficial effects in rodent OS models.

Purpose of the Study:

• To investigate the synergistic effects of PEDF treatment and uPAR downregulation in human osteosarcoma cells.
• To elucidate the molecular mechanisms underlying the interaction between PEDF and the uPAR system in OS progression.

Main Methods:

• In silico analysis of PEDF binding to uPA.
• Cell-based assays using human OS cells treated with PEDF and/or uPAR inhibitors (antibody, DNAzyme).
• Analysis of clinical OS specimens for PEDF and uPAR expression.
• In vivo studies in animal models to assess tumor growth, metastasis, and osteolysis.

Main Results:

• PEDF did not directly inhibit uPA activity but influenced the intracellular localization of uPA, uPAR, and FAK in OS cells.
• Blocking cell surface uPA and uPAR enhanced PEDF binding.
• Clinical OS samples showed mutually exclusive expression of PEDF and uPAR at the tumor margin.
• Combined PEDF and uPAR targeting significantly reduced OS cell invasion, increased apoptosis, inhibited primary tumor growth and pulmonary metastasis, and decreased osteolysis in vivo.

Conclusions:

• A combined therapeutic approach involving PEDF and uPAR knockdown demonstrates significant anti-osteosarcoma effects.
• The study reveals a complex interplay between PEDF and the uPAR system in osteosarcoma progression.
• Targeting both PEDF and uPAR represents a promising strategy for developing novel osteosarcoma therapies.